Ultrasound-guided intraperitoneal cisplatin after the maximum cytoreductive surgery of pseudomyxoma peritonei
Bulletin of Alexandria Faculty of Medicine. 2008; 44 (4): 729-734
in English
| IMEMR
| ID: emr-99555
ABSTRACT
In the past, pseudomyxoma peritonei was considered an incurable disease and often no active treatment was given. With the advent of cyto-reductive surgery, including peritonectomy procedures and intra peritoneal chemotherapy, long-term survival of these patients became actually possible. To study the impact of the intraperitoneal hyperthermic chemotherapy [cisplatin], when locally administered in patients who presented with pseudomyxoma peritonei and were treated by extensive cyto-reductive surgery. Nine patients with and. peritoneal adenomucinosis or carcinomatosis arising from the appendix who presented with a clinical picture of pseudomyxoma peritonei were diagnosed, and treated by cyto-reductive surgery followed by 6 cycles of ultrasound-guided intraperitoneal hyperthermic cisplatin. Following aggressive surgical approach and intraperitoneal chemotherapy, 7 patients had 1 year disease free survival, achieved independent activity in daily living and had an improved quality of life. The other 2 patients developed recurrences at 8 and 10 months following the completion of treatment. No major [grade III] texicities were observed. Pseudomyxoma peritonei is a treatable condition that may result in long-term disease free survival. Successful management can be achieved by combining cyto-reductive surgery and intraperitoneal hyperthermic chemotherapy
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Pathology
/
Surgical Procedures, Operative
/
Biopsy
/
Carcinoembryonic Antigen
/
Tomography, X-Ray Computed
/
Survival Rate
/
Ultrasonography
/
Cisplatin
/
Injections, Intraperitoneal
/
Neoplasm Metastasis
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Bull. Alex. Fac. Med.
Year:
2008
Similar
MEDLINE
...
LILACS
LIS